This informational website is developed by Chiesi USA, and is intended only for residents of the United States

Ferriprox® (deferiprone) is a prescription medicine used to treat iron overload from blood transfusions in people with:

  • thalassemia syndromes
  • sickle cell disease or other anemias

Ferriprox Tablets are for adults and children ≥8 years of age; Ferriprox Oral Solution is for patients ≥3 years of age.

It is not known if Ferriprox is safe and effective to treat iron overload due to blood transfusions:

  • in people with myelodysplastic syndrome or Diamond Blackfan anemia
  • in children less than 3 years of age

Learn more about Ferriprox >

Iron removal (chelation) is important for you if you receive repeated blood transfusions for the treatment of sickle cell disease.

As iron builds up in the body, complications happen more often.

Ferriprox has been shown to provide effective liver iron reduction at 1 year with continuous reduction over 3 years.1

Ferriprox was studied in a 1-year, controlled non-inferiority clinical trial of 185 people with sickle cell disease. 122 patients received Ferriprox and 63 received deferoxamine over 1 year.

In the clinical trial, the mean decrease in liver iron concentration (LIC) from baseline was -4.13 mg/g dw ± 0.50 after 1 year of treatment with Ferriprox compared to 4.38 mg/g dw ± 0.59 for deferoxamine1

People treated with Ferriprox experienced an additional 30% reduction in liver iron level after 3 years of therapy. LIC dropped from 14.93 mg/g dw at baseline to 10.45 mg/g dw after 3 years of treatment.1

A review of clinical trials from 2018 found that people with sickle cell disease with iron overload† had higher rates of:

DEATH 64% compared to 5% for those without iron overload

ORGAN FAILURE 71% compared to 19% for those without iron overload

PAIN EPISODES 64% experienced ≥3 pain episodes per year compared to 38% for those without iron overload

Another clinical study in 199 transfused people with sickle cell disease compared to 64 non-transfused people with sickle cell disease also showed an increase in the number of:

HOSPITAL STAYS 4.1 hospitalizations per year compared to. 2.1 for non-transfused people (p<0.001)

DEATHS17 The death rate in adults with sickle cell disease who receive transfusions is 3 times higher than the general US population.

†Defined as serum ferritin levels >1500 ng/mL and transferrin saturation >50%. Without iron overload was defined as serum ferritin levels <100 and transferrin saturation <50%.

A large study of >1,000 people with sickle cell anemia showed that kidney failure was responsible for 14% of deaths in people with sickle cell disease.

Ferriprox has not been proven to impact outcomes such as death, organ function, or symptoms such as pain episodes.

Iron chelation therapy is most beneficial when it is started early and taken as prescribed

The ASH guidelines recommend T2* MRI screening of the liver and heart be performed for sickle cell disease patients.

ASH guidelines recommend liver iron overload MRI T2* every 1 to 2 years

Liver iron overload should be checked by MRI every 1 to 2 years if you receive regular transfusions.

ASH guidelines recommend heart MRI T2* if you have:

  • sickle cell disease with a high iron burden (liver iron content >15 mg/g [dry weight (dw)]) for 2 years or more
  • evidence of end organ damage because of transfusional iron overload
  • or evidence of cardiac dysfunction

Use the MRI T2* facility search to find the one nearest you

Ferriprox is an oral medication that is taken either as a tablet or a liquid solution.

Ferriprox offers a Twice-A-Day formulation.

Talk to your healthcare provider about the formulation you prefer.

Choose your Ferriprox formulation

Yes. Ferriprox is suitable for patients with reduced kidney or liver function. No change of the Ferriprox dose is required in patients with a mild to severe reduction in kidney function or a mild to moderate reduction in liver function.

† Ferriprox was not studied in patients with severely reduced liver function.

Talk to your doctor about switching to the Ferriprox Twice-A-Day formulation >

Your doctor will do a blood test before you start Ferriprox and weekly during treatment to check your neutrophil count. Neutrophils are a type of white blood cell and are important for fighting infections. If you develop a low neutrophil count (neutropenia) your healthcare provider should check your blood counts every day until your white blood cell count improves. Your healthcare provider may temporarily stop treatment with Ferriprox if you develop neutropenia or infection.

During treatment, your doctor will also do monthly blood tests to check your liver function. If necessary they may also check your zinc levels.

Read more important information >

If you develop a fever, sore throat or mouth sores, flu-like symptoms, or chills and severe shaking follow these 3 steps:

stop

Stop the drug immediately

doctor

Seek medical attention immediately (i.e., go to the ER or your doctor)

bottle

Notify the ER provider or your doctor that you are taking a medication that can cause agranulocytosis

A wallet card with these three steps printed on it is included in every one of your Ferriprox medication shipments. To learn more or request a wallet card, call the Chiesi Total CareSM team at: 1-866-758-7071.

Visit Chiesi Total Care >

Ferriprox is available in:

  • 1000 mg Twice-A-Day tablets
  • 1000 mg Three-Times-A-Day tablets
  • 500 mg Three-Times-A-Day tablets
  • 100 mg/mL Three-Times-A-Day oral solution

Ferriprox offers a Twice-A-Day formulation. This means you get the same proven iron reduction with fewer doses per day. Talk to your doctor and pharmacist today about switching to the Ferriprox Twice-A-Day formulation.

Chiesi Total CareSM offers one-stop patient support. A single call to your dedicated Chiesi Total Care team is all it takes to guide you through the process of getting started on Ferriprox therapy. Visit chiesitotalcare.com or call 1-866-758-7071. We’re ready to help!

Meet your support team >

IMPORTANT SAFETY INFORMATION

What is Ferriprox® (deferiprone)?

Ferriprox® (deferiprone) is a prescription medicine used to treat iron overload from blood transfusions in people with:1

  • thalassemia syndromes
  • sickle cell disease or other anemias

Ferriprox Tablets are for adults and children ≥8 years of age; Ferriprox Oral Solution is for patients ≥3 years of age.

It is not known if Ferriprox is safe and effective to treat iron overload due to blood transfusions:

  • in people with myelodysplastic syndrome or Diamond Blackfan anemia
  • in children less than 3 years of age

What is the most important information I should know about Ferriprox?

Ferriprox can cause serious side effects, including a very low white blood cell count. One type of white blood cell that is important for fighting infections is called a neutrophil. If your neutrophil count is low (neutropenia), you may be at risk of developing a serious infection that can lead to death. Neutropenia is common with Ferriprox and can become severe in some people. Severe neutropenia is known as agranulocytosis. If you develop agranulocytosis, you will be at risk of developing serious infections that can lead to death.

Your healthcare provider should do a blood test before you start Ferriprox and weekly during treatment to check your neutrophil count. If you develop neutropenia, your healthcare provider should check your blood counts every day until your white blood cell count improves. Your healthcare provider may temporarily stop treatment with Ferriprox if you develop neutropenia or infection.

Stop taking Ferriprox and get medical help right away if you develop any of these symptoms of infection: fever, sore throat or mouth sores, flu-like symptoms, or chills and severe shaking.

What is Ferriprox® (deferiprone)?

Ferriprox® (deferiprone) is a prescription medicine used to treat iron overload from blood transfusions in people with:1

  • thalassemia syndromes
  • sickle cell disease or other anemias

Ferriprox Tablets are for adults and children ≥8 years of age; Ferriprox Oral Solution is for patients ≥3 years of age.

It is not known if Ferriprox is safe and effective to treat iron overload due to blood transfusions:

  • in people with myelodysplastic syndrome or Diamond Blackfan anemia
  • in children less than 3 years of age

Important Safety Information

Do not take Ferriprox if you are allergic to deferiprone or any of the ingredients in Ferriprox.

Before you take Ferriprox, tell your healthcare provider about all of your medical conditions, including if you: have liver problems, are pregnant or plan to become pregnant. Ferriprox can harm your unborn baby. You should avoid becoming pregnant during treatment with Ferriprox. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Ferriprox. For females who are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with Ferriprox. You should use effective birth control during treatment with Ferriprox and for at least 6 months after the last dose. For males with female partners who are able to become pregnant, you should use effective birth control during treatment with Ferriprox and for at least 3 months after the last dose. Talk to your doctor if you are breastfeeding or plan to breastfeed. It is not known if Ferriprox passes into your breast milk. Do not breastfeed during treatment with Ferriprox and for at least 2 weeks after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

Avoid drinking alcohol during treatment with Ferriprox tablets (2 times a day). This may cause a faster release of the medicine.

What are other possible side effects of Ferriprox?

Ferriprox can cause serious side effects, including increased liver enzyme levels in your blood. Your healthcare provider should do monthly blood tests to check your liver function during treatment with Ferriprox.

Ferriprox can cause decreased levels of zinc in your blood. Your healthcare provider will do blood tests to check your zinc levels during treatment with Ferriprox and may prescribe a zinc supplement for you if your zinc levels are low.

The most common side effects of Ferriprox in people with thalassemia include nausea, vomiting, stomach-area (abdominal) pain, joint pain, abnormal liver function tests and low white blood cells.

The most common side effects of Ferriprox in people with sickle cell disease or other anemias include fever, stomach-area (abdominal) pain, bone pain, headache, vomiting, pain in arms or legs, sickle cell anemia with crisis, back pain, abnormal liver function tests, joint pain, mouth and throat pain, common cold, low white blood cells, cough and nausea.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

Please see Full Prescribing Information, including boxed WARNING, and Medication Guide.

IMPORTANT SAFETY INFORMATION

What is Ferriprox® (deferiprone)?

Ferriprox® (deferiprone) is a prescription medicine used to treat iron overload from blood transfusions in people with:1

  • thalassemia syndromes
  • sickle cell disease or other anemias

Ferriprox Tablets are for adults and children ≥8 years of age; Ferriprox Oral Solution is for patients ≥3 years of age.

It is not known if Ferriprox is safe and effective to treat iron overload due to blood transfusions:

  • in people with myelodysplastic syndrome or Diamond Blackfan anemia
  • in children less than 3 years of age

What is the most important information I should know about Ferriprox?

Ferriprox can cause serious side effects, including a very low white blood cell count. One type of white blood cell that is important for fighting infections is called a neutrophil. If your neutrophil count is low (neutropenia), you may be at risk of developing a serious infection that can lead to death. Neutropenia is common with Ferriprox and can become severe in some people. Severe neutropenia is known as agranulocytosis. If you develop agranulocytosis, you will be at risk of developing serious infections that can lead to death.

Your healthcare provider should do a blood test before you start Ferriprox and weekly during treatment to check your neutrophil count. If you develop neutropenia, your healthcare provider should check your blood counts every day until your white blood cell count improves. Your healthcare provider may temporarily stop treatment with Ferriprox if you develop neutropenia or infection.

Stop taking Ferriprox and get medical help right away if you develop any of these symptoms of infection: fever, sore throat or mouth sores, flu-like symptoms, or chills and severe shaking.

What is Ferriprox® (deferiprone)?

Ferriprox® (deferiprone) is a prescription medicine used to treat iron overload from blood transfusions in people with:1

  • thalassemia syndromes
  • sickle cell disease or other anemias

Ferriprox Tablets are for adults and children ≥8 years of age; Ferriprox Oral Solution is for patients ≥3 years of age.

It is not known if Ferriprox is safe and effective to treat iron overload due to blood transfusions:

  • in people with myelodysplastic syndrome or Diamond Blackfan anemia
  • in children less than 3 years of age

Important Safety Information

Do not take Ferriprox if you are allergic to deferiprone or any of the ingredients in Ferriprox.

Before you take Ferriprox, tell your healthcare provider about all of your medical conditions, including if you: have liver problems, are pregnant or plan to become pregnant. Ferriprox can harm your unborn baby. You should avoid becoming pregnant during treatment with Ferriprox. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Ferriprox. For females who are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with Ferriprox. You should use effective birth control during treatment with Ferriprox and for at least 6 months after the last dose. For males with female partners who are able to become pregnant, you should use effective birth control during treatment with Ferriprox and for at least 3 months after the last dose. Talk to your doctor if you are breastfeeding or plan to breastfeed. It is not known if Ferriprox passes into your breast milk. Do not breastfeed during treatment with Ferriprox and for at least 2 weeks after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

Avoid drinking alcohol during treatment with Ferriprox tablets (2 times a day). This may cause a faster release of the medicine.

What are other possible side effects of Ferriprox?

Ferriprox can cause serious side effects, including increased liver enzyme levels in your blood. Your healthcare provider should do monthly blood tests to check your liver function during treatment with Ferriprox.

Ferriprox can cause decreased levels of zinc in your blood. Your healthcare provider will do blood tests to check your zinc levels during treatment with Ferriprox and may prescribe a zinc supplement for you if your zinc levels are low.

The most common side effects of Ferriprox in people with thalassemia include nausea, vomiting, stomach-area (abdominal) pain, joint pain, abnormal liver function tests and low white blood cells.

The most common side effects of Ferriprox in people with sickle cell disease or other anemias include fever, stomach-area (abdominal) pain, bone pain, headache, vomiting, pain in arms or legs, sickle cell anemia with crisis, back pain, abnormal liver function tests, joint pain, mouth and throat pain, common cold, low white blood cells, cough and nausea.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

Please see Full Prescribing Information, including boxed WARNING, and Medication Guide.

You are now leaving Ferriprox.com

Please be aware that the sponsors of this site are not responsible for content on the site you are about to enter.Continue to external siteStay on current page